终端αGlcNAc糖基可能作为人胰腺癌细胞肿瘤标志物的初步研究

Terminal a-N-acetyiglucosamine residues possibly serve as one of the signs for humanpancreatic cancer

目的探索终端为α-N-乙酰葡萄糖胺（αGlcNAc）糖基在胰腺癌组织和细胞中是否呈现特异高表达，从而确定终端αGlcNAc糖基是否可能作为胰腺癌的肿瘤标志物。方法利用特异性识别表位为终端αGlcNAc的商业化抗体（HIK1083），应用免疫组化方法，对11例胰腺癌患者和5例正常人胰腺组织进行检测。结果HIK1083抗体对11例胰腺癌组织／细胞均有明显的结合活性，而对正常胰腺组织和细胞无反应。结论终端αGlcNAc糖基可能作为胰腺癌细胞的肿瘤标志物，对胰腺癌的临床靶向治疗和诊断具有重要的研究价值。

Objective To explore the significant expression of terminal a-N-acetylglucosamine （aGlcNAc） residues in the tissues of pancreatic cancer and to determine if the residues could serve as one of the signs for pancreatic cancer. Methods The pancreatic tissues obtained from eleven pancreatic cancer patients and five normal subjects were analyzed by immunohistochemistry with commercial antibody HIK1083, which specially recognized the terminal aGlcNAc residues. Results The antibody, HIK1083, demonstrated a significant combination with the pancreatic tissues from cancer patients, but not in normal counterparts. Conclusion Terminal aGlcNAc residues might serve as the tumor marker for pancreatic cancers, and reflected a great value for implication in target treatment and diagnosis of pancreatic cancers.